600196 復星醫藥
按盤價 
22.890 +0.030 (+0.131%) | 2026/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 20,441,970 | 4.75% | 41,661,613 | 41,067,196 | 41,399,540 | 43,951,547 | |
| 減：營業總成本 | 19,682,628 | 4.12% | 40,087,325 | 39,397,512 | 41,284,077 | 41,346,264 | |
| 其中:營業成本 | 10,288,189 | 1.63% | 20,800,103 | 21,365,574 | 21,595,309 | 23,169,690 | |
| 財務費用 | 531,063 | -17.06% | 1,153,425 | 1,110,518 | 984,323 | 647,403 | |
| 資產減值損失 | (14,943) | -76.75% | (150,063) | (96,570) | (219,742) | (272,488) | |
| 公允價值變動收益 | 273,652 | -663.11% | (322,268) | (115,939) | (427,380) | (2,498,368) | |
| 投資收益 | 1,493,305 | -29.57% | 3,763,778 | 2,104,607 | 3,501,993 | 4,377,843 | |
| 其中：對聯營企業和合營企業的投資收益 | 1,135,355 | 22.13% | 1,923,979 | 1,643,839 | 2,184,849 | 1,835,146 | |
| 營業利潤 | 2,615,941 | -5.26% | 5,228,351 | 4,245,104 | 3,307,508 | 4,656,656 | |
| 利潤總額 | 2,586,572 | -4.85% | 5,111,983 | 4,169,282 | 3,264,568 | 4,574,382 | |
| 減：所得稅費用 | 437,643 | -29.21% | 864,054 | 656,841 | 369,504 | 626,917 | |
| 淨利潤 | 2,148,928 | 2.32% | 4,247,930 | 3,512,440 | 2,895,063 | 3,947,464 | |
| 減：非控股權益 | 427,461 | 7.34% | 877,368 | 742,554 | 508,798 | 216,660 | |
| 股東淨利潤 | 1,721,468 | 1.15% | 3,370,562 | 2,769,887 | 2,386,266 | 3,730,805 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.650 | 1.56% | 1.270 | 1.040 | 0.890 | 1.430 | |
| 每股派息 (元) * | -- | -- | 0.390 | 0.320 | 0.270 | 0.420 | |
| 每股淨資產 (元) * | 18.248 | 2.81% | 18.252 | 17.700 | 17.110 | 16.684 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 27/08/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
